Sk Life Drug Patent Portfolio
Sk Life owns 1 orange book drug protected by 2 US patents Given below is the list of Sk Life's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11654133 | Use of [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate in combination therapy | 16 Jun, 2039 | Active |
| US7598279 | Neurotherapeutic azole compounds | 30 Oct, 2032 | Active |
Latest Legal Activities on Sk Life's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Sk Life.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Electronic Review
Critical
| 07 Jun, 2024 | US7598279 |
| Mail Pub Notice re 312 amendment | 20 Mar, 2024 | US7598279 |
|
Email Notification
Critical
| 20 Mar, 2024 | US7598279 |
| Post Issue Communication - Certificate of Correction Denied | 15 Mar, 2024 | US7598279 |
| POST ISSUE OTHER COMMUNICATION TO APPLICANT- CERTIFICATE OF CORRECTION | 14 Mar, 2024 | US7598279 |
|
Patent Term Extension Certificate
Critical
| 09 Nov, 2023 | US7598279 |
| Notice of Final Determination -Eligible | 09 Aug, 2023 | US7598279 |
|
FDA Final Eligibility Letter
Critical
| 13 Jul, 2023 | US7598279 |
| Recordation of Patent eGrant | 23 May, 2023 | US11654133 |
|
Recordation of Patent Grant Mailed
Critical
| 23 May, 2023 | US11654133 |
| Patent eGrant Notification | 23 May, 2023 | US11654133 |
|
Electronic Review
Critical
| 23 May, 2023 | US11654133 |
| Mail Patent eGrant Notification | 23 May, 2023 | US11654133 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 23 May, 2023 | US11654133 |
|
Email Notification
Critical
| 23 May, 2023 | US11654133 |
Sk Life's Family Patents
Sk Life drugs have patent protection in a total of 19 countries. It's US patent count contributes only to 9.5% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click
below to unlock the full patent family tree.
Sk Life Drug List
Given below is the complete list of Sk Life's drugs and the patents protecting them.
1. Xcopri
Xcopri is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11654133 | Use of [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate in combination therapy |
16 Jun, 2039
(13 years from now)
| Active |
| US7598279 | Neurotherapeutic azole compounds |
30 Oct, 2032
(7 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xcopri's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List